We are conducting a study using Fitbit and prescription data from the NIH-funded All of Us Research Program to examine how GLP-1 receptor agonists (GLP-1 RAs) and physical activity jointly impact cardiometabolic health. GLP-1 RAs, used for type 2 diabetes and obesity, may reduce cardiovascular disease (CVD) risk, and their effects may be enhanced by physical activity.
We will assess adults aged 18–75 with at least 6 months of data to: (1) compare cardiometabolic outcomes between GLP-1 RA users and non-users among Fitbit wearers; and (2) test whether step counts modify the effect of GLP-1 RAs. The primary outcome is incident CVD (heart attack, stroke, heart failure); secondary outcomes include changes in A1c and BMI over 6–12 months.
This project offers an excellent opportunity for students with R programming experience or those interested in improving their R skills through applied research.